Logo

Invicro/Konica Minolta Precision Medicine: Matthew Silva and Jack Hoppin

Dec 23, 2019

Invicro, a Konica Minolta Company focused on imaging for translational drug discovery and development, has appointed Matthew Silva as CEO. Silva, who will also join Invicro's board, joined the company in 2012 and was most recently executive vice president of scientific applications. He has also worked in leadership positions at Vertex, Amgen, Millenium, and Takeda Pharmaceuticals.

Silva will replace Jack Hoppin as Invicro's CEO. Hoppin is a cofounder of the company and will move from his role as Invicro CEO to be the president of Konica Minolta Precision Medicine. Hoppin will also serve on the boards of both companies.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.